Floatz logo

THIENO(3,2-D)PYRIMIDIN-2-AMINE, 7-(4-FLUORO-2-METHOXYPHENYL)-6-METHYL-N-(1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL)-

Acute Myelogenous Leukemia (AML)

Maxinovel Pty., Ltd.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

685 Active assets in the Acute Myelogenous Leukemia (AML) cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

THIENO(3,2-D)PYRIMIDIN-2-AMINE, 7-(4-FLUORO-2-METHOXYPHENYL)-6-METHYL-N-(1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL)- is also rated in:

Advanced / Metastatic Solid TumorsDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →